Archives
Following a summer of uncertainty post Brexit, investors all over the world are returning from summers spent on the beach, ready to do some serious M&A business to close out the year. We have seen a comparatively quiet year for M&A when you look at the figures for 2015, with deal values in the UK around half of the $215 billion that were announced at the same time in 2015 (Thomson Reuters… Read More
Think healthcare M&A is on its way out in 2016? Think again. Following the surprising failure in April of the deal between Pfizer and Allergan, many analysts have raised concerns that a similar pattern will ensue within healthcare deal making. While the collapse of the $160bn deal was unexpected, and brought total value of abandoned deals this year to its highest since the eve of the financial crisis at $376bn, industry experts… Read More